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Although the risk of developing cardiovascular disease (CVD) is reduced by the 
Mediterranean diet1, CVD prevalence in Spain is rising. CVD is a major cause of 
mortality and morbidity in this country, and there is a growing awareness in the scientific 
community of the need for advances in knowledge, diagnosis, and therapy.  
Spain has a strong tradition of basic research in molecular biology, immunology, 
development, neuroscience, and oncology, but historically there have been few research 
groups dedicated to basic cardiovascular research, and this has been reflected in limited 
funding. Over the last 20 years, a national strategy to address this situation has seen the 
creation of a cardiovascular center of excellence and research networks focused on CVD. 
This significant boost to Spanish cardiovascular research has generated closer 
collaboration between the clinical and basic research communities, with already tangible 
beneficial results. Here, we outline current trends in cardiovascular research in Spain, 
highlighting achievements, opportunities, and challenges. 
  
Cardiovascular research in Spain – facts and figures 
Grants and Funding 
Despite increasing CVD incidence and prevalence, public research funding in Spain has 
decreased over the last decade. This cut in funds follows a general trend in Spain in the 
wake of the global financial crisis. Basic and translational cardiovascular research groups 
have obtained around 300 competitive grants over the last 8 years, securing close to 50 
million euros (Fig. 1A). Most national grants are awarded to one, or sometimes two, 
principal investigators and are usually small, ranging 80,000-120,000 euros for a 3 year 
project. 
Over the last 15 years, the Instituto de Salud Carlos III (Carlos III National 
Institute of Health; ISCIII) has provided an additional funding stream to support thematic 
research networks. These networks are multidisciplinary and bring together basic and 
clinical researchers in an effort to elucidate new disease mechanisms and develop new 
diagnostic and therapeutic tools that will ultimately improve healthcare. The CVD 
dedicated network (CIBERCV) is discussed below in more detail. Another source of 
funding for CVD studies and training is the Sociedad Española de Cardiología (Spanish 
Society of Cardiology; SEC). Grants from the SEC are small (≤20,000 euros per project), 
but the SEC funds a large number of projects every year. 
Spanish cardiovascular research groups also receive significant support from 
international sources, with 50 groups awarded competitive international grants amounting 
more than 26 million euros over the last 5 years (Fig. 1B). These are mainly European 
Union grants awarded to networks of researchers working toward a shared goal. Some of 
these networks focus more on research training (Innovative Training Networks, ITN), 
while others are fully focused on research. Although the number of European grants with 
participating Spanish groups is increasing and approaching that of other countries with a 
stronger tradition in cardiovascular research, there is still room for improvement. 
European grant calls (especially within the current Horizon 2020 programme) have taken 
on a more clinical and applied slant, forcing closer interactions between basic and clinical 
researchers. The transition to more applied collaborative research is already underway in 
Spain thanks to the initiatives mentioned above, and this established trend should 
therefore increase Spanish participation in continental networks. 
 
Publications 
Despite the historical difficulties outlined above, Spanish cardiovascular research groups 
have a strong record in high impact publication. In the last 5 years, cardiovascular 
research groups published more than 2500 papers. Of these, 68% were published in 
journals with an impact factor in the first quartile and 29% of publications were in the 
first decile. These figures are higher than the average impact of Spanish papers published 
in the medical sciences, of which 48% were published in Q1 journals. Moreover, in 2014 
the normalized citation impact for Spanish cardiovascular research papers (the number of 
citations for these papers divided by the average number of citations for all papers in the 
same period and field) was 2.9, compared with 1.4 for all Spanish medical science papers 
in the same period. Consistent with these indicators, 29% of the 2500 papers were among 
the top 10% cited papers in their area, and more than 100 were among the top 1%. The 
citation distribution per paper is shown in Fig. 1C. 
 Almost two thirds of these articles were published in clinical journals, followed 
by journals specialized in molecular biology & genetics, biochemistry, pharmacology, 
and immunology (Fig. 1D). A keywords analysis for each paper showed enrichment for 
major cardiovascular conditions, including heart failure, atrial fibrillation, myocardial 
infarction and stroke, atherosclerosis, and terms related to prognosis and treatment, 
imaging, and major CVD symptoms (Fig. 1E).  
 Together, these data show that cardiovascular research in Spain is in good health 
despite the funding restraints, with strength in clinical and translational cardiology as well 
as in molecular biology, genetics, and immunology. 
 
Challenges and opportunities 
Personalized medicine and big data 
Spain has a world-class public healthcare system, and the integration of different hospital 
databases into larger regional and national resources opens up new possibilities for the 
analysis of big data and the development of personalized medicine. In this regard, new 
projects characterizing participants at the clinical, behavioral, and molecular level have 
emerged. A prime example is the PESA study (Progression of Early Subclinical 
Atherosclerosis)2, led by the CNIC (see below). This study is a unique initiative in 
Spanish research, not only in terms of cohort size (n=4000), but also because of the deep 
patient phenotyping and the original funding scheme. The long-term CVD-dedicated 
PESA study is funded by an innovative public-private partnership in which the public 




Traditionally, as in other areas of the Mediterranean basin, Spanish citizens have tended 
to live close to their families and place of birth. From a scientific perspective, this 
translates into large pedigrees that considerably facilitate genetic studies. Patients and 
their families are generally keen to cooperate with such studies and represent a major 
resource for the identification of CVD-associated mutations. In addition, patients are 
usually well phenotyped, and clinicians are willing to share valuable samples in order to 
improve genetic studies. These features of the Spanish cultural landscape have been 
exploited for the study of several diseases, including dilated, hypertrophic, and 
arrhythmogenic right ventricular cardiomyopathies.  
 
Medical engineering and Imaging 
In recent years a strong bond has emerged between biomedicine, engineering, and 
physics, extending to the creation of new university departments and degrees. This 
partnership has contributed to the development of new research and diagnostic imaging 
tools, including both hardware and software. In addition, joint efforts by engineers and 
cardiovascular researchers have facilitated the development of image post-processing 
methods that have improved the accuracy of diagnostic imaging. 
 
Regenerative medicine 
At the beginning of the 2000s, Spanish researchers enthusiastically embraced the various 
initiatives in regenerative medicine, particularly in relation to regenerative cardiology. 
This discipline bloomed with the creation of new departments in major research institutes, 
international meetings held in Spain, and government financial support. Although the 
financial crisis slowed the pace of research somewhat, several research groups maintain 
active research programs on regenerative medicine in the cardiovascular field. Spanish 
groups led a recent position paper by the Transnational Alliance for Regenerative 
Therapies in Cardiovascular Syndromes (TACTICS)3, which was created with the goal 
of improving clinical applications in cardiovascular regenerative medicine. This 
document will pave the way for future translational regenerative research and illustrates 
Spanish leadership in collaborative approaches to translational regenerative medicine. 
 
New paradigms in translational cardiovascular research in Spain 
To bridge the divide between basic and clinical research, the Spanish government 
launched two initiatives more than 10 years ago: the CNIC, a research center of excellence 
founded in 1999 and focused on translational cardiovascular research, and the CIBERCV, 




The CNIC is a modern research institute founded by the Spanish Ministry of Health to 
tackle the CVD epidemic4. Covering a total floor space of 23,000 m2, the center was 
equipped from the outset with the latest scientific equipment and technical units, and has 
built a powerful, cross-disciplinary research base that embraces basic research as well as 
population and clinical studies. Under the leadership of Dr. Valentín Fuster since 2005, 
the CNIC is financed through an innovative public-private financing structure that 
includes direct governmental funding through the ISCIII and private sector through the 
Pro CNIC Foundation (a diverse consortium of 14 leading Spanish companies and 
charitable foundations). The CNIC has also achieved major success in securing 
competitive funding, with CNIC groups coordinating several European FP7 and H2020 
projects and securing 10 European Research Council (ERC) individual grants in the last 
few years. The center’s performance is monitored by an external Scientific Advisory 
Board, which makes recommendations about the recruitment of new group leaders and 
evaluates all of the CNIC’s scientific activities and the performance of its group leaders 
according to an up-or-out system.  
The CNIC is establishing strong bonds with hospitals across Spain (and 
internationally) to promote closer integration between basic and clinical research. To 
boost these interactions, between 2008 and 2013 the CNIC funded collaborative 
translational research projects (only 25% of them led by CNIC researchers) with a total 
of 6.4 million euros (~800,000 euros per project). Landmark clinical trials arising from 
this highly successful CNIC-translational initiative included the PREDIMED1 and 
METOCARD-CNIC trials5. CNIC also coordinates European initiatives that include the 
participation of many Spanish clinical centers, for example the SECURE and FOCUS 
trials6 within the “Fuster-CNIC-Ferrer” Cardiovascular polypill initiative led by CNIC 
General Director Valentín Fuster. 
 
CIBERCV 
In 2002, the ISCIII launched a funding scheme for thematic networks, with three networks 
dedicated to CVD research (RECAVA, REDINSCOR, and HERACLES). In 2012, the 
ISCIII decided to strengthen their cardiovascular research program by integrating these 
into one single network (Red de Investigación Cardiovascular, RIC). The RIC included 
64 groups distributed in 7 specific research programs. With the restructuring of the 
thematic networks in 2016, the RIC was reformulated as a virtual center, the Centro de 
Investigación Biomédica en Red de Enfermedades Cardiovasculares (Biomedicine 
Research Network Center for Cardiovascular Research; CIBERCV). The CIBERCV 
includes 40 Spanish groups from 24 institutions across Spain, with the groups selected 
through a competitive external evaluation based on scientific excellence. The CIBERCV 
provides more funding and greater flexibility than the previous networks, and is organized 
into 4 dedicated programs (myocardial damage, arterial disease, heart failure and 
structural heart disease), and 2 transverse initiatives (biomarkers and epidemiology). 
More than 2 million euros are distributed to CIBERCV groups every year through a 
competitive internal procedure. Periodical evaluation is expected to generate a 5-10% 
turnover, facilitating the entry of emerging groups into the network. 
 
Conclusions 
Cardiovascular research in Spain was boosted in the last years thanks to national 
initiatives (launching the cardiovascular center of excellence CNIC, and creating 
research networks focused on CVD). Despite the economic constrains affecting the 
national budget dedicated to research, Spanish groups in the CVD field are becoming 
more competitive in the international (European) arena. Scientific output of Spanish 
CVD-dedicated groups is especially strong given the relatively small mean financial 
support per research group. The growing collaboration between basic and clinical 
researchers should further increase the competitiveness of Spanish consortia. 
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